| Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem … I Tzannou, A Papadopoulou, S Naik, K Leung, CA Martinez, CA Ramos, ... Journal of Clinical Oncology 35 (31), 3547, 2017 | 418 | 2017 |
| Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT A Papadopoulou, U Gerdemann, UL Katari, I Tzannou, H Liu, C Martinez, ... Science translational medicine 6 (242), 242ra83-242ra83, 2014 | 415 | 2014 |
| Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant U Gerdemann, UL Katari, A Papadopoulou, JM Keirnan, JA Craddock, ... Molecular Therapy 21 (11), 2113-2121, 2013 | 251 | 2013 |
| Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis A Papadopoulou, M Yiangou, E Athanasiou, N Zogas, P Kaloyannidis, ... Annals of the rheumatic diseases 71 (10), 1733-1740, 2012 | 138 | 2012 |
| Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and … E Yannaki, T Papayannopoulou, E Jonlin, F Zervou, G Karponi, ... Molecular Therapy 20 (1), 230-238, 2012 | 72 | 2012 |
| The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant‐induced arthritis in rats E Yannaki, A Papadopoulou, E Athanasiou, P Kaloyannidis, A Paraskeva, ... Arthritis & Rheumatism 62 (11), 3277-3288, 2010 | 69 | 2010 |
| Genetic justification of severe COVID-19 using a rigorous algorithm E Gavriilaki, PG Asteris, T Touloumenidou, EE Koravou, M Koutra, ... Clinical Immunology 226, 108726, 2021 | 57 | 2021 |
| Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks PG Asteris, E Gavriilaki, T Touloumenidou, EE Koravou, M Koutra, ... Journal of cellular and molecular medicine 26 (5), 1445-1455, 2022 | 51 | 2022 |
| Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges A Papadopoulou, P Kaloyannidis, E Yannaki, CR Cruz Critical Reviews in Oncology/Hematology 98, 62-72, 2016 | 39 | 2016 |
| Systemic inflammatory response syndrome after administration of unmodified T lymphocytes A Papadopoulou, RA Krance, CE Allen, D Lee, CM Rooney, MK Brenner, ... Molecular Therapy 22 (6), 1134-1138, 2014 | 37 | 2014 |
| Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host A Papadopoulou, M Alvanou, K Koukoulias, E Athanasiou, A Lazaridou, ... Bone Marrow Transplantation 54 (12), 1963-1972, 2019 | 18 | 2019 |
| The diverse genetic origins of a Classical period Greek army LJ Reitsema, A Mittnik, B Kyle, G Catalano, PF Fabbri, ACS Kazmi, ... Proceedings of the National Academy of Sciences 119 (41), e2205272119, 2022 | 17 | 2022 |
| Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia E Yannaki, N Psatha, E Athanasiou, G Karponi, V Constantinou, ... Human gene therapy 21 (3), 299-310, 2010 | 16 | 2010 |
| Vaccinated and convalescent donor-derived SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients PG Papayanni, E Siotou, A Boutou, E Gavriilaki, C Giannaki, I Kioumis, ... Clinical Infectious Diseases, 2021 | 15* | 2021 |
| Reinforcing the immunocompromised host defense against fungi: progress beyond the current state of the art G Karavalakis, E Yannaki, A Papadopoulou Journal of Fungi 7 (6), 451, 2021 | 11 | 2021 |
| “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients K Koukoulias, PG Papayanni, A Georgakopoulou, M Alvanou, S Laidou, ... Frontiers in Immunology 11, 608701, 2021 | 10 | 2021 |
| In vivo hematopoietic stem cell genome editing: perspectives and limitations N Psatha, K Paschoudi, A Papadopoulou, E Yannaki Genes 13 (12), 2222, 2022 | 9 | 2022 |
| SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial A Papadopoulou, G Karavalakis, E Papadopoulou, A Xochelli, Z Bousiou, ... Nature Medicine 29 (8), 2019-2029, 2023 | 8 | 2023 |
| Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients E Gavriilaki, A Papadopoulou, T Touloumenidou, F Stavridou, ... Bone Marrow Transplantation 57 (7), 1183-1186, 2022 | 8 | 2022 |
| Pathogen-specific T cells: targeting old enemies and new invaders in transplantation and beyond A Papadopoulou, M Alvanou, G Karavalakis, I Tzannou, E Yannaki Hemasphere 7 (1), e809, 2023 | 7 | 2023 |
Evangelia YannakiUNIVERSITY OF WASHINGTON, GEORGE PAPANIKOLAOU HOSPITALΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα uw.edu
